Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis
Authors:
- 1 February 2021
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 160 (3) , 932-934.e3
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Molecular Pathways of Colon Inflammation Induced by Cancer ImmunotherapyCell, 2020
- Tofacitinib for Refractory Immune-Related Colitis from PD-1 TherapyNew England Journal of Medicine, 2020
- Immune-related adverse events of checkpoint inhibitorsNature Reviews Disease Primers, 2020
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseJournal of Clinical Oncology, 2020
- Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center studyJournal for ImmunoTherapy of Cancer, 2018
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitisNature Medicine, 2018
- Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell, 2017
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaNew England Journal of Medicine, 2016
- Immune Checkpoint Blockade in Cancer TherapyJournal of Clinical Oncology, 2015